Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.
Novo Nordisk raised its outlook for its full-year sales and operating profit on soaring demand for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.for its full-year sales and operating profit due to soaring demand for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.
The revised forecast only confirms the frenzy for those weekly injections, which patients seek for their ability to help them lose significant weight over time. Ozempic and Wegovy have propelled Novo Nordisk to become Europe's The Danish drugmaker now expects 2023 sales growth in local currencies of 32% to 38%, from a previous outlook of 27% to 33%, according to a press release.The new sales outlook for this year primarily reflects higher expectations for Ozempic sales in the U.S. and "gross-to-net sales adjustments for Ozempic and Wegovy in the U.S.," according to the release.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk warns online offers of fake Ozempic, Wegovy are risingNovo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
Read more »
Novo Nordisk: Online Ozempic, Wegovy Fakes RisingNovo Nordisk warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.'Novo Nordisk has seen a significant increase...
Read more »
Novo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surgeNovo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surge
Read more »
Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and WegovyEleanor Laise is a healthcare reporter for MarketWatch and is based in Washington.
Read more »
Novo Nordisk raises full-year guidance again as US sales of Wegovy, Ozempic flyNovo Nordisk (NOVOb.CO) on Friday raised its outlook for its full-year sales and operating profit for the third time this year, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States.
Read more »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »